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Colorectal cancer (CRC) remains a significant cause of mortality. Inhibitors of cyclooxygenase (COX) and thus
prostaglandin E2, are promising CRC preventives, but have significant toxicities. Ginger has been shown to inhibit COX, to
decrease the incidence andmultiplicity of adenomas, and decrease PGE2 concentrations in subjects at normal risk for CRC.
This study was conducted to determine the effects of 2.0 g/d of ginger given orally on the levels of PGE2, leukotriene B4
(LTB4), 13-hydroxy-octadecadienoic acids, and 5-, 12-, & 15-hydroxyeicosatetraenoic acid, in the colonic mucosa of
subjects at increased risk for CRC.We randomized 20 subjects to 2.0 g/d ginger or placebo for 28 d. At baseline andDay 28,
a flexible sigmoidoscopy was used to obtain colon biopsies. A liquid chromatography mass spectrometry methodwas used
to determine eicosanoid levels in the biopsies, and levels were expressed per amount of protein or free arachidonic acid
(AA). There was a significant decrease in AA between baseline and Day 28 (P¼0.05) and significant increase in LTB4
(P¼ 0.04) when normalized to protein, in subjects treated with ginger versus placebo. No other changes in eicosanoids
were observed. There was no difference between the groups in total adverse events (AE; P¼0.06). Ginger lacks the ability
to decrease eicosanoid levels in people at increased risk for CRC. Ginger did appear to be both tolerable and safe; and could
have chemopreventive effects through other mechanisms. Further investigation should focus on other markers of CRC risk
in those at increased CRC risk. © 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Despite recent decreases in mortality, colorectal
cancer (CRC) remains the third most prevalent and
second most deadly cancer in the United States [1].
Non-steroidal anti-inflammatory drugs (NSAIDs),
which inhibit cyclooxygenase 1 & 2 (COX-1 & 2)
enzymes and thus lower the levels of the inflamma-
tory prostaglandin E2 (PGE2) are promising colorectal
cancer (CRC) chemopreventive agents [2]. However,
the gastrointestinal and cardiovascular side-effects of
aspirin and other NSAIDs have raised concerns for
their daily prescription to an otherwise healthy
population [3,4]. Also, there is some thought that
the inhibition of COX enzymes by these drugs could
cause the shunting of arachidonic acid (AA), the
substrate for COX, towards the production of other
inflammatory eicosanoids [5]. In particular, various
eicasanoids produced by the lipoxygenase (LOX)
enzymes (5-, 12-, & 15-LOX) from AA, which are
leukotriene B4 (LTB4) and the hydroxyeicosatetrae-
noic acids (HETEs), 5-, 12-, & 15-HETE and 13-
hydroxyoctadecadienoic acid (13-HODE) produced
from linoleic acid. Leukotriene B4 and 5- & 12-HETE
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have all been implicated in the development of
CRC [6–12], while both 15-HETE and 13-HODE
appear to have anti-inflammatory and anti-tumori-
genic activities [13–15]. Therefore, using natural
nutritional components with low toxicity, which
have the potential to affect COX and LOX, and their
products is a potential area of investigation for the
prevention of CRC.
One such natural nutritional compound is ginger
root (Zingiber officinale),which has been shown to
inhibit 5-LOX [16–19] and COX-1 & -2 [18,20–22].
Ginger root decreases inflammation in various mu-
rine models [16,23–26], and reduces serum concen-
trations of PGE2 in rats [27]. Ginger root has also
demonstrated preventative effects by decreasing
tumor size, incidence and multiplicity in chemically
induced animal models of colon carcinogenesis [28–
30]. When ginger was administered in the post-
initiation stage, it did not suppress aberrant crypt foci
formation nor did ginger significantly change the
proliferative or apoptotic indexes of the colonic
crypt [31]. In our recent studies in participants at
normal and increased risk for CRC we found that
ginger significantly lowered COX-1 protein expres-
sion in increased risk participants, but not in normal
risk participants [32]. In another study, ginger
significantly reduced gut tissue concentrations of
PGE2 and 5-HETE and with a trend toward significant
decreases in 12-HETE and 15-HETE in participants at
normal risk for CRC [33].
The purpose of this study was to expand on our
previous work in subjects at normal risk for CRC by
examining the effect of 2.0 g of ginger taken daily for
28 days compared to placebo on eicosanoids in the
colonic mucosa of subjects at increased risk for
developing colorectal cancer. Secondary objectives
were to evaluate the safety, tolerability, adherence
and blinding of ginger supplementation.
MATERIALS AND METHODS
Study Participants
Fliers and word-of mouth were used to recruit 21
participants from the Ann Arbor, MI area between
June 2009 and January 2010. Eligible participants had
to be generally healthy individuals 18 years or older,
who were at increased risk for CRC defined as having
at least one of the following: (1) a first degree relative
with CRC before the age of 60; (2) a previous
adenomatous polyp; (3) or early stage resected (Dukes
A, B, orC) colon cancer. Subjectswere excluded if they
were: lactose intolerant; had a diagnosis of peptic
ulcer disease, gastrointestinal bleeding, or gastrin
secreting tumors; had a known allergy to ginger; were
taking supplements or medications which could
obscure the ability to detect anti-inflammatory
effects; and pregnant or lactating women. Also
persons with hereditary non-polyposis colon cancer
or familial adenomatous polyposis (HNPCC/FAP),
inflammatory bowel disease, or coagulopathy disor-
ders were excluded. Participants were told to stop
eating any foods containing ginger within 14 days
before drug administration and given a list of ginger-
rich foods to avoid. All participants were reimbursed
for their time.
The University of Michigan Institutional Review
Board approved this study and all participants gave
written, informed consent before beginning any
study procedures. This study was conducted at the
University of Michigan Clinical Research Unit
(MCRU).
Ginger Intervention
Details on quality control of the ginger extract have
been previously published [33]. Briefly, a 2.0 g dose of
powered ginger root extract (Z. officinale) standard-
ized to 15mg (5%) of total gingerols and manufac-
tured by Pure Encapsulations1 (Sudbury, MA) was
used in the study. This was the same ginger product
used in our previous trials with identical amount (5%)
of total gingerols. The 2.0 g dose of ginger was based
on themaximum tolerated dose of ginger in a phase 1
study in healthy volunteers [34]. Lactose was used for
the placebo capsules. Both the lactose and ginger
powder were placed into identical opaque red
capsules by the Investigational Drug Service (IDS) of
the University of Michigan.
Toxicity of the intervention was evaluated at
weekly intervals using The National Cancer Institute
(NCI) Common Toxicity Scale V 4.02 [35].
Randomization, Allocation, Adherence, and Blinding
Participants were randomized equally into the
placebo or ginger group. The study biostatistician
generated the randomization code, whichwas kept by
the University of Michigan IDS. The next available
randomization number was assigned by the IDS as
eligible participants were identified. Participants and
study personnel were unaware of the randomization
list or treatment assignment. To determine if partic-
ipants were blind to treatment allocation, partic-
ipants were asked at their final visit which treatment
they received (“ginger,” “placebo” or “don’t know”).
Adherence was assessed by weekly telephone calls,
self-report, and pill counts at the end of the study.
Adherence was defined as taking at least 70% of
capsules as prescribed.
Flexible Sigmoidoscopy and Tissue Collection
Two flexible sigmoidoscopies, one at baseline and
the secondwithin 24h of the last ginger/placebo dose
on Day 28 were performed. Participants were not
asked to fast or to undergo any bowel cleansing
preparation. Participants were placed in a left lateral
decubitus position and a flexible sigmoidoscope was
passed at least 15 cm above the anal sphincter and
eight tissue samples were obtained. Each biopsy
specimen was taken 2 cm or more from other biopsy
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sites in the distal sigmoid colonic mucosa by opening
and pressing the biopsy forceps perpendicular to the
mucosal surface with mild pressure.
Tissue Handling and Disposition
Biopsies were frozen in liquid nitrogen and then
stored at708Cafter being placed into a sterile 1.5-mL
Eppendorf tube. Biopsy samples were taken at
precisely 50 s after the time the biopsy forceps were
closed. Biopsies weighed approximately 5mg and
contained between 400 and 600mg protein. Eicosa-
noids assays were run in triplicate and required
around 10–20mg of colon tissue, which is the
equivalent of two biopsies.
Analytical Methods
Eicosanoids (PGE2, 5-HETE, 12-HETE, 15-HETE and 13-
HODE)
Eicosanoids were assayed according to previously
reported methods [33,36,37] Briefly, reverse-phase
LC electrospray ionization mass spectrometry (LC/
MS/MS) analyses were used for quantitation of PGE2,
LTB4, 5-HETE, 12-HETE, 15-HETE, and 13-HODE. LC/
MS/MS analyses were performed using a Quattro
Ultima tandem mass spectrometer (Micromass,
Beverly, MA) equipped with an Agilent HP 1100
binary pump HPLC inlet. Eicosanoids were separated
using a Luna 3m Phenyl-Hexyl 2mm150mm LC
column (Phenomenex, Torrance, CA). The mobile
phase consisted of 10mM ammonium acetate (pH
8.5) and methanol. For the analysis of PGE2, HETEs,
and 13-HODE, the separation was achieved using a
linear methanol gradient from 40% to 60% over
18min followed by a methanol flush. The flow rate
was 250mL/min with a column temperature of 508C.
The sample injection volume was 25mL. Samples
were kept at 48C during the analysis. All eicosanoids
were detected using electrospray negative ionization
and multiple-reaction monitoring of the transition
ions for the metabolites and their internal
standards [38].
The mass spectrometer (Thermo Finnigan TSQ
Quantum, San Jose, CA) was operated in the electro-
spray negative ion mode with a cone voltage of
2300V, a cone gas flow rate of 117l/h, and a
devolution gas flow rate of 998l/h. The temperature
of the desolvation region was 3508C, and the
temperature of the source region was 1208C. Frag-
mentation for all compounds was performed using
argon as the collision gas at a collision cell pressure of
2.10103 Torr. The collision energy ranged from 16
to 31V depending on the analyte. The results were
either expressed as nanogram (ng) of eicosanoid per
milligram (mg) of protein or as ng of eicosanoid per
microgram (mg) of free AA. All of the biopsy samples
from a given individual were assayed in the same
batch to eliminate any batch effects over time.
Statistical Methods and Sample Size
Statistical analyses were conducted using SAS 9.2
statistical software (SAS Institute Inc., Cary, NC). A P-
value 0.05 (two-sided) was considered statistically
significant. Baseline characteristics stratified by treat-
ment group were analyzed and reported as mean
standard deviations (SD) for continuous variables,
and as counts and percentages for categorical varia-
bles. Balance between treatment groups on baseline
characteristicswas tested using independent sample t-
tests for continuous variables and Pearson’s Chi-
square and Fisher exact tests, as appropriate, for
categorical variables.
We calculated the mean percent change within
treatment group, for PGE2, LTB4, 5-HETE, 12-HETE,
15-HETE, and 13-HODE from baseline to Day 28.
Results are reported as mean SD. Pearson’s Chi-
square or Fisher’s exact test were used to calculate
between group differences for adverse events.
Assessment of blinding and adherence were deter-
mined using an independent sample t-test to deter-
mine the difference in the proportion of participants
in each group who correctly guessed their correct
group assignment or who took 70% or greater of their
study medication. Mean and SD for percent adherent
per group was tested using independent sample t-test.
We determined using a two sample t-test that a
sample size of 10 per treatment group would have
better than 80% power and a 5% level of significance
to detect a reduction of at least 25% mean difference
in PGE2 mucosal concentration in the ginger group
compared to the placebo group at the end of a 28d
intervention. This is based on previously reported
data on PGE2 levels in participants at increased risk of
CRC human colon tissue who had baseline PGE2
mucosal concentrations of 14.4, 1.7pg/mg protein,
which decreased after 28 d of 81mg of asprin to a
mean concentration of 4.70.70pg/mg protein
which was roughly a 70% reduction compared to
the placebo group [39].
RESULTS
Subjects and Toxicity
We screened 47 persons of whom 21 met all
eligibility criteria andwere randomized: 11 to placebo
and 10–2.0 g ginger, for 28 d. However, one partici-
pant randomized to the placebo group was removed
from study after it was determined that he was not at
increased risk for CRC. Figure 1 documents the
numbers of participants, reasons for exclusions and
reasons for discontinuing the intervention.
Table 1 reports demographic and clinical character-
istics by group. No significant differences for any
demographic or clinical characteristic between treat-
ment groups were found. The mean age of the study
subjects was 51.012.9 (range 29–73 yr) with less
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than half of the participants being male (N¼7,
35.0%). The majority of the participants self-reported
as being Caucasian (N¼15, 75.0%), with two (25%)
indicating that they were African American (N¼2),
American Indian (N¼2), or mixed race (N¼1), while
none of the participants reported being of Hispanic
ethnicity. The majority of participants (N¼10,
50.0%) were at increased risk for CRC due to having
had a prior adenoma (N¼12, 60.0%), and seven
subjects had a first degree relative with a diagnosis of
CRC before the age of 60. Only one participant had a
history of early stage colon cancer (5%), and three
participants had multiple reasons (both a prior
adenoma and a first degree relative) for being at
increased colon cancer risk.
Possible, probably or likely treatment-related tox-
icities are reported by participants in Table 2. All
adverse events were non-serious and reported as grade
1 per theNCICommonToxicityCriteria (v. 4.02) [35].
No significant difference was observed between the
groups for total adverse events (N¼13, P¼0.06) or
among specific categories of adverse events such as
gastrointestinal (GI) toxicities (N¼10, P¼0.18).
Eicosanoids (PGE2, LTB4, 5-HETE, 12-HETE, 15-HETE, and
13-HODE)
In Table 3, all continuous outcomes and mean
percent change frombaseline toDay 28 of PGE2, LTB4,
5-, 12-, 15-HETE, 13-HODE, and AA are shown
normalized to both protein and AA, with the
exception of AA. The baseline values of PGE2, LTB4,
5-HETE, 12-HETE, 15-HETE, and 13-HODE in colon
biopsies across both groups were 11.812.8,
2.601.7, 6.36.3, 2.71.8, 10.113.6, and
47.277.5 pg/mg protein, respectively (mean SD,
n¼20). Baseline values normalized to AA of PGE2,
LTB4, 5-HETE, 12-HETE, 15-HETE, and 13-HODEwere
1.41.2, 0.50.7, 1.95.0, 0.50.6, 1.93.2, and
4.98.1ng/mg, respectively.
There was no significant difference inmean percent
change between the placebo and ginger group for any
of the eicosanoids when normalized to AA after 28 d.
In contrast, when normalized to protein there was a
significant increase (P¼0.04) in LTB4 in the ginger
group (4.754.9% placebo versus 54.063.2%
ginger) and a significant (P¼0.05) decrease in AA in
the ginger group (229.4413.7% placebo versus
44.241.5% ginger). There were no other signifi-
cant differences in the other eicosanoids.
Figure 1. Flow diagram of a trial of ginger supplementation over 4
wk on eicosanoids in normal-appearing colorectal mucosa of individu-
als at increased risk of for colorectal cancer
Table 1. Baseline Characteristics of the Randomization
Groups
Characteristics
Ginger
(N¼ 10)
Placebo
(N¼10) P-value
Sex, no. (%)
Men 4 (40) 3 (30) 0.64a
Women 6 (60) 7 (70)
Race, no. (%)
White 8 (80) 7 (70) 0.38a
Age, mean (SD), yr 51.1 (11.7) 50.8 (14.6) 0.95b
Reason for being high risk for CRCc, no. (%)
First degree relatived 4 (40.0) 6 (60.0) 0.47b
Previous adenoma 5 (50.0) 4 (40.0)
Previous CRC 1 (10.0) 0 (0.0)
aP-value is based on an independent samples t-test.
bP-value is based on a Chi-Squared.
cCRC, colorectal cancer.
dFirst degree relative diagnosedwith colorectal cancer before
the age of 60 yr.
Table 2. Adverse Events Reported by Person
Adverse Events
Ginger
(n¼ 10)
Placebo
(n¼ 10) P-valuea
All participants with
any AE, No. (%)
9 (90.0) 4 (40.0) 0.06
CGIb 7 (70.0) 3 (30.0) 0.18
Otherc 3 (30.0) 1 (10.0) 0.58
aP-value: Chi-Square or Fisher’s exact test as appropriate.
bGI symptoms includes: bloating, urgency, gas, nausea,
heartburn, sores in mouth & anorexia.
cOther includes: allergic reaction, nose bleed, skin rash,
struck with water tube after biopsy procedure.
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Blinding and Adherence
Participantswere unable to determinewhether they
had received ginger or placebo (P¼0.53). The
majority of participants (N¼9, 45.0%) indicated
they were taking placebo, with seven participants
reporting ginger (35.0%) and four (20.0%) being
unable to decide to which treatment they were
randomized.
Participants on average took 79.17.4% of their
capsules and all participants were adherent per our
definition of taking at least 70% of their capsules with
a mean SD of 78.48.6% in the placebo group and
79.86.6% in the ginger group. There was no
significant difference in adherence between treat-
ment groups (P¼0.70).
DISCUSSION
We found that ingesting 2.0 g per d of ginger root
extract for 28 d significantly decreased AA and
significantly increased concentrations of LTB4,
when normalized to protein, in normal appearing
gut mucosa in participants who were at increased risk
of developing colon cancer. Ginger had no significant
effect on any other eicosanoid including PGE2 in gut
tissue whether normalized to protein or AA. Although
not statistically significant, the concentrations of all
eicosanoids were increased, and in some cases to a
large extent, in the ginger treatment group compared
to the placebo group at the end of a 28d intervention
using either method of normalization. Of import,
however, mean percent increases in eicosanoid
concentrations were accompanied by a high level
of variability implying that the response to ginger
was highly heterogeneous with some participants
experiencing no change, others decreases in and
others large increases in eicosanoid concentrations.
These findings are in contrast to previous studies in
humans as well as those conducted in a rat model and
in vitro. Whole ginger root and various ginger
constituents have been shown to inhibit leukotriene
synthesis by blocking 5-LOX activity [21,40], reduce
COX-1 and COX-2 activity and subsequently reduce
concentrations of PGE2 in a variety of cell lines [20–
22,41–47], and significantly reduce serum levels of
PGE2 in female Sprague–Dawley rats given 50mg/kg
ginger extract daily [27]. Our previous work in
participants at normal risk for CRC showed that a
2.0g dose of ginger root extract given for 28 d
significantly reduced PGE2 concentrations in colonic
mucosa [33].Wealsodemonstrated thatCOX-1protein
expression was significantly reduced in participants at
increased risk forCRC (those reportedon, in this study),
although it remained unchanged in participants at
normal risk [32]. In contrast, a study by Black and
colleagues sawno significant difference in plasma PGE2
levels in healthy volunteers after 28 d of taking 2.0g of
either raw or heat treated ginger root [48]. Different to
previous studies, but in agreement with our results, a
study in 21 people with knee and hip osteoarthritis
found that 28 d of ingesting a 340mg of a standardized
ginger extract (EV.EXT35) significantly increased levels
of several prostaglandins including PGE2 in the
stomach mucosa [49].
Table 3. Eicasanoids Levels in Normal Mucosa in Participants at Increased Risk for Colorectal Cancer [Mean (SD)]
Eicosanoid
Placebo (n¼10) Ginger (n¼ 10)
P-valueaBaseline After 28 d Mean % changeb Baseline After 28 d Mean % changeb
Standardized to protein (pg/mg)
PGE2 12.9 (15.2) 12.8 (16.8) 37.0 (113.4) 10.6 (10.5) 23.6 (21.2) 333.5 (773.6) 0.26
LTB4 2.9 (1.7) 2.6 (2.1) 4.7 (54.9) 2.4 (1.9) 3.5 (2.3) 54.0 (63.2) 0.04
HETE5 8.9 (8.0) 9.0 (8.0) 39.1 (108.9) 3.7 (2.0) 15.2 (14.0) 412.1 (755.6) 0.16
HETE12 3.2 (2.2) 5.1 (5.5) 59.4 (149.1) 2.2 (1.3) 4.5 (4.4) 101.7 (196.1) 0.60
HETE15 14.7 (17.7) 11.1 (9.8) 82.1 (189.5) 5.5 (5.6) 20.6 (18.8) 602.5 (1047.8) 0.16
HODE13 41.4 (50.8) 30.9 (22.0) 27.7 (105.2) 53.0 (100.1) 35.0 (32.6) 55.7 (122.4) 0.59
AA (ng/pg)c 1.0 (1.3) 1.4 (1.4) 229.4 (413.7) 1.6 (1.1) 0.7 (0.4) 44.2 (41.5) 0.05
Standardized to arachidonic acid (ng/mg)
PGE2 1.7 (1.4) 3.70 (8.4) 147.6 (368.7) 1.0 (1.0) 3.0 (2.9) 1149.2 (3194.5) 0.17
LTB4 0.7 (1.0) 0.34 (0.3) 84.3 (205.9) 0.2 (0.2) 0.5 (0.4) 173.8 (248.9) 0.27
HETE5 3.4 (6.9) 1.72 (2.5) 362.7 (718.9) 0.4 (0.3) 2.4 (3.7) 1079.6 (2297.0) 0.15
HETE12 0.7 (0.7) 0.57 (0.5) 247.1 (598.9) 0.2 (0.1) 0.6 (0.7) 279.2 (487.4) 0.38
HETE15 3.3 (4.1) 2.00 (3.2) 290.6 (545.8) 0.5 (0.5) 3.2 (5.2) 1406.3 (2993.3) 0.13
HODE13 6.8 (10.9) 4.98 (6.3) 140.5 (453.7) 3.1 (3.4) 4.4 (4.5) 114.1 (164.02) 0.23
SD, standard deviation.
aIndependent t-test of the difference between the mean percent change from baseline to Day 28.
bMeanpercent change betweenbaseline andWeek4 is calculated as [(eicosanoid at time2/eicosanoid at time 1)/eicosanoid at
time 1)] per participant and then an average is obtained.Meanpercent changemaynot appear reflective of change in baseline
and 28-d follow-up mean values. This is due to the large amount of variability in the baseline measures.
cAA, arachidonic acid; PGE2, prostaglandin E2; 5-HETE, 12-HETE, 15-HETE, 5-, 12- & 15-hydroxyeicosatetraenoicacid;
13-HODE, 13-hydroxy-octadecadienoic acids.
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Differences between these various studies could be
due to different doses and formulations of the ginger
products, the absorption and metabolism of ginger in
in vivo environments; or differential effects of ginger
on different tissue types or in situations of underlying
inflammation. A clear challenge with natural health
products, such as ginger, is the heterogeneity of ginger
preparations. A few in vitro studies have shown
significant differences between various ginger constit-
uents in impacting COX enzyme activity and PGE2
production [22,42,46].However, systematic differences
in structure and function of various ginger constituents
have not been examined in animal models or humans,
thus making it unclear if different ginger formulations
would behave differently in in vivo situations.
Underlying the importance of examining the effect
of ginger in humans and on tissues of interest is the
possible differential effects of ginger on different
tissue cell types or in situations of underlying
inflammation. While ginger and its components
appear to decrease the production of inflammatory
products such as PGE2 and LTB4, many of these
studies were conducted in isolated cell lines and quite
a few in murine macrophages (RAW 264.7) using
lipopolysaccharide (LPS)-elicited production of PGE2.
In vitro studies such as these are useful for exploring
possible mechanisms, but they do not model the
complex biological interactions that occur in animals
or humans. For instance the study by Drozdov and
colleagues [49] found that PGE2 and related eicosa-
noids were elevated in gastric tissue after ginger
consumption and they also found an increased
concentration of PGE2 in the gastric mucosa.
Another interpretation of our findings, if eciosa-
noids are good biomarkers of CRC risk, is that ginger
may not be an effective CRC prevention agent.
Alternately, although a controversial idea, is that
inhibition of inflammatory eciosanoids may not
equate with prevention of CRC. There is a robust
and growing body of evidence that NSAIDs may not
act via their conventional anti-COX effects for colon
cancer prevention [50]. Consequently, itmay bemore
fruitful for future investigations to focus on ginger’s
effect on underlying biological pathways rather than
basing ginger’s evaluation on biochemistry such as
eicosanoid levels. Numerous in vitro studies have
shown significant impacts on various cell cycle
markers [51,52]. Moreover, research in people at
increased risk of CRC have demonstrated significant
effects of ginger on proliferation, differentiation, and
apoptosis markers [53].
This study had several limitations, which include a
small sample size, a short intervention period, and a
fairly large amount of variability in eicosanoid levels.
This was intended to be a pilot study for a larger
human trial. Thus, it is possible that extended ginger
consumption and more study participants might
provide additional power to detect the effects of
dietary ginger root intake on various prostaglandin
pathways. Further, the small sample size did not allow
us to conduct additional subgroup analyses by risk
type, for example, family history, previous adenoma,
previous CRC nor by sociodemographic variables
such as age, race, and gender. This study would need
to be further replicated in larger trials, which would
have adequate power to examine several independent
groups defined by baseline colonic mucosal eicosa-
noid concentrations to account for the presence of
low levels of inflammation. Also, future studies may
need to focus on outcomes with less variability than
tissue eicosanoids such as proliferation, differentia-
tion, and apoptosis markers, which have already been
demonstrated to be significantly affected in humans
by ginger [53].
In summary, 28 d of supplementation with ginger
root extract in participants who were at increased risk
for CRC caused a significant decrease in normal
colonic mucosa of AA and significantly increased
concentrations of LTB4, when normalized to protein.
Ginger had no significant effect on any other
eicosanoid including PGE2 in colon tissue whether
normalized to protein or AA. Ginger did increase
eicasanoids other than PGE2, as compared to placebo,
when normalized to either AA or protein, but these
increases were not statistically significant. Future,
larger studies with ginger supplementation should
perhaps focus on other biomarker outcomes.
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